GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (NAS:EVO) » Definitions » Cyclically Adjusted Book per Share

Evotec SE (Evotec SE) Cyclically Adjusted Book per Share : $2.16 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Evotec SE Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Evotec SE's adjusted book value per share for the three months ended in Mar. 2024 was $3.392. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.16 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 24.80% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 21.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Evotec SE was 24.80% per year. The lowest was 10.80% per year. And the median was 20.50% per year.

As of today (2024-06-15), Evotec SE's current stock price is $4.55. Evotec SE's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $2.16. Evotec SE's Cyclically Adjusted PB Ratio of today is 2.11.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Evotec SE was 19.99. The lowest was 2.10. And the median was 11.69.


Evotec SE Cyclically Adjusted Book per Share Historical Data

The historical data trend for Evotec SE's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Cyclically Adjusted Book per Share Chart

Evotec SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.98 1.19 1.41 1.74 2.11

Evotec SE Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.96 1.94 2.11 2.16

Competitive Comparison of Evotec SE's Cyclically Adjusted Book per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Evotec SE's Cyclically Adjusted PB Ratio falls into.



Evotec SE Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Evotec SE's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=3.392/125.0381*125.0381
=3.392

Current CPI (Mar. 2024) = 125.0381.

Evotec SE Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.812 99.543 1.020
201409 0.763 99.823 0.956
201412 0.743 99.543 0.933
201503 0.672 99.717 0.843
201506 0.770 100.417 0.959
201509 0.753 100.417 0.938
201512 0.763 99.717 0.957
201603 0.764 100.017 0.955
201606 0.786 100.717 0.976
201609 0.815 101.017 1.009
201612 0.846 101.217 1.045
201703 1.257 101.417 1.550
201706 1.202 102.117 1.472
201709 1.291 102.717 1.572
201712 1.329 102.617 1.619
201803 1.416 102.917 1.720
201806 1.396 104.017 1.678
201809 1.542 104.718 1.841
201812 1.621 104.217 1.945
201903 1.699 104.217 2.038
201906 1.655 105.718 1.957
201909 1.688 106.018 1.991
201912 1.759 105.818 2.079
202003 1.788 105.718 2.115
202006 1.773 106.618 2.079
202009 1.833 105.818 2.166
202012 2.692 105.518 3.190
202103 2.869 107.518 3.337
202106 3.120 108.486 3.596
202109 3.537 109.435 4.041
202112 4.407 110.384 4.992
202203 4.076 113.968 4.472
202206 3.810 115.760 4.115
202209 3.437 118.818 3.617
202212 3.554 119.345 3.724
202303 0.000 122.402 0.000
202306 3.590 123.140 3.645
202309 3.436 124.195 3.459
202312 3.446 123.773 3.481
202403 3.392 125.038 3.392

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Evotec SE  (NAS:EVO) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Evotec SE's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=4.55/2.16
=2.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Evotec SE was 19.99. The lowest was 2.10. And the median was 11.69.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Evotec SE Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Evotec SE's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Evotec SE (Evotec SE) Business Description

Industry
Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.